Changing from preserved, to preservative-free cyclosporine 0.1% enhanced triple glaucoma therapy: impact on ocular surface disease – a randomized controlled trial

Konstas A.-G., Boboridis K. G., Athanasopoulos G. P., Haidich A.-B., Voudouragkaki I. C., Pagkalidou E., Katsanos A., Katz L. J.

2023
Eye

View publication

Therapeutic Area

Glaucoma
Categories

Clinical development

Affiliations

University Department of Ophthalmology, Aristotle University of Thessaloniki, Thessaloniki, Greece; Department of Epidemiology, Aristotle University of Thessaloniki, Thessaloniki, Greece; Department of Ophthalmology, University of Ioannina, Ioannina, Greec; Glaucoma Research Center, Wills Eye Hospital, Philadelphia, PA, USA

Related Publications

Felodipine re-positioned as a neuroprotectant via improved optic nerve head blood circulation in retinal ischemic rabbits and ocular hypertensive rats

Taniguchi T, Akaishi T, Hata T, Yamashita R, Esaki Y, Morofuji R, Okabe K, Fuwa M, Yamamoto Y, Guo L, Choi S, Luong V, Ota T, Sharif NA, Cordeiro MF, Kageyama M.

A Study of 24-h Efficacy and Safety of Sepetaprost vs. Latanoprost in Patients with Primary Open-Angle Glaucoma or Ocular Hypertension

Konstas A.G.; Garhöfer G.; Lübke Y.; Voykov B.; Ropo A.

Valproic Acid Application to Modify Post Surgical Fibrosis in a Model of Minimally Invasive Bleb Surgery

Lo P.F.; Gunawan M.; Yap Z.L.; Leong C.; Kwek F.; Varadarajan J.; Wang X.; Kageyama M.; Wong T.T.

View all Glaucoma publications